Magdalena Olszanecka-Glinianowicz1, Paweł Madej2, Aleksander Owczarek3, Jerzy Chudek4, Piotr Skałba2. 1. Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. 2. Department of Endocrinological Gynecology, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland. 3. Division of Statistics in Sosnowiec, Faculty of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Katowice, Poland. 4. Pathophysiology Unit, Department of Pathophysiology, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Abstract
OBJECTIVE: The aim of the study was to analyse the relationship between nutritional status, selected adipokines and plasma anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). STUDY DESIGN PATIENTS AND MEASUREMENTS: A prospective, cross-sectional study, involving 87 PCOS (48 obese) women and 67 non-PCOS women (36 obese). Anthropometric parameters were measured, and body composition was determined by the bioimpedance method. Fasting serum glucose, androgens, FSH, LH, SHBG, insulin, AMH, apelin-36, adiponectin, leptin and omentin-1 were measured. RESULTS: Plasma AMH levels were significantly higher in PCOS compared to the non-PCOS group (7.8 ± 4.3 ng/ml vs 44 ± 2.4 ng/ml; P < 0.001). Furthermore, AMH levels were higher in both PCOS and non-PCOS normal weight than in obese subgroups (8.9 ± 4.4 ng/ml vs 7.0 ± 4.0 ng/ml; P < 0.05 and 5.1 ± 2.4 ng/ml vs 3.9 ± 2.3 ng/ml; P < 0.05). There were negative correlations between AMH levels and anthropometric parameters (body mass, BMI, fat mass and percentage, as well as waist circumference) and plasma omentin-1 concentrations (R = -0.28, P < 0.001; R = -0.30, P < 0.001; R = -0.36, P < 0.001; R = -0.34, P < 0.001; R = -0.23, P < 0.01; and R = -0.20, P < 0.05, respectively) in all study groups. In multiple regression analysis, circulating AMH level variability was explained by omentin-1 levels and anthropometric parameters (excluding waist circumference). CONCLUSIONS: In this observational study, nutritional status appears to be the main factor influencing circulating AMH levels independent of PCOS. The observed AMH association with omentin-1 levels suggests that this adipokine may be a link between hormonal dysfunction of adipose tissue related to obesity and decreased AMH secretion.
OBJECTIVE: The aim of the study was to analyse the relationship between nutritional status, selected adipokines and plasma anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). STUDY DESIGN PATIENTS AND MEASUREMENTS: A prospective, cross-sectional study, involving 87 PCOS (48 obese) women and 67 non-PCOSwomen (36 obese). Anthropometric parameters were measured, and body composition was determined by the bioimpedance method. Fasting serum glucose, androgens, FSH, LH, SHBG, insulin, AMH, apelin-36, adiponectin, leptin and omentin-1 were measured. RESULTS: Plasma AMH levels were significantly higher in PCOS compared to the non-PCOS group (7.8 ± 4.3 ng/ml vs 44 ± 2.4 ng/ml; P < 0.001). Furthermore, AMH levels were higher in both PCOS and non-PCOS normal weight than in obese subgroups (8.9 ± 4.4 ng/ml vs 7.0 ± 4.0 ng/ml; P < 0.05 and 5.1 ± 2.4 ng/ml vs 3.9 ± 2.3 ng/ml; P < 0.05). There were negative correlations between AMH levels and anthropometric parameters (body mass, BMI, fat mass and percentage, as well as waist circumference) and plasma omentin-1 concentrations (R = -0.28, P < 0.001; R = -0.30, P < 0.001; R = -0.36, P < 0.001; R = -0.34, P < 0.001; R = -0.23, P < 0.01; and R = -0.20, P < 0.05, respectively) in all study groups. In multiple regression analysis, circulating AMH level variability was explained by omentin-1 levels and anthropometric parameters (excluding waist circumference). CONCLUSIONS: In this observational study, nutritional status appears to be the main factor influencing circulating AMH levels independent of PCOS. The observed AMH association with omentin-1 levels suggests that this adipokine may be a link between hormonal dysfunction of adipose tissue related to obesity and decreased AMH secretion.
Authors: Lia A Bernardi; Mercedes R Carnethon; Peter J de Chavez; Deborah E Ikhena; Lisa M Neff; Donna D Baird; Erica E Marsh Journal: Obesity (Silver Spring) Date: 2016-12-07 Impact factor: 5.002
Authors: Margaret C Garin; Samantha F Butts; David B Sarwer; Kelly C Allison; Suneeta Senapati; Anuja Dokras Journal: Endocrine Date: 2016-12-21 Impact factor: 3.633
Authors: Barbara J Stegmann; Mark Santillan; Benjamin Leader; Elaine Smith; Donna Santillan Journal: Fertil Steril Date: 2015-06-19 Impact factor: 7.329
Authors: Agnieszka Adamska; Anna Popławska-Kita; Katarzyna Siewko; Agnieszka Łebkowska; Anna Krentowska; Angelika Buczyńska; Łukasz Popławski; Piotr Szumowski; Małgorzata Szelachowska; Adam Jacek Krętowski; Irina Kowalska Journal: Front Endocrinol (Lausanne) Date: 2021-07-29 Impact factor: 5.555